A Phase III, Open-Label, Randomized Study Of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
This randomized, open-label study is designed to evaluate the efficacy and safety of
atezolizumab (anti-programmed death ligand 1 [PD-L1] antibody) plus bevacizumab versus
sunitinib in participants with inoperable, locally advanced, or metastatic renal cell
carcinoma (RCC) who have not received prior systemic active or experimental therapy, either
in the adjuvant or metastatic setting.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society